Novel Therapeutics for Duchenne Muscular Dystrophy, 2018 Market Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Novel
Therapeutics for Duchenne Muscular Dystrophy”
report has been
added to ResearchAndMarkets.com’s offering.

This Genetic Technology TOE depicts life sciences trends in therapeutics
for Duchenne’s muscular dystrophy. The topics covered range from gene
editing approaches to breakthrough muscle-on-a-chip innovations.

Clinical trial analysis of important investigational therapeutics for
Duchenne muscular dystrophy is also presented.

The complete gamut of genetic technology applications is covered
including the latest developments in omics technologies; genetic,
cellular, and alternative therapies; sequencing technologies; and
genetically altered animals and plants.

Key Topics Covered:

Recent Advances in Development of Novel Therapeutics for
Duchenne Muscular Dystrophy

  • CRISPR-based Therapeutic in Development for Duchenne Muscular Dystrophy
  • Multiple Treatment Development for Diverse DMD Population
  • Solid Biosciences’ IGNITE DMD Clinical Trial to Resume
  • Muscle-on-a-chip Platform for DMD Target Discovery

Clinical Trial Analysis and Key Contacts

  • Clinical Trial Analysis of Important Investigational Therapeutics for
    Duchenne Muscular Dystophy
  • Key Contacts

For more information about this report visit https://www.researchandmarkets.com/research/f5grgq/novel?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs
, Musculoskeletal
Disorders Drugs